Apimeds Pharmaceuticals US (APUS) Non-Current Debt (2025)
Apimeds Pharmaceuticals US's (APUS) quarterly Non-Current Debt came in at $250000.0 in Q1 2025.
Apimeds Pharmaceuticals US (APUS) Non-Current Debt (2025) Analysis & Trends
Apimeds Pharmaceuticals US (APUS) has 1 years of Non-Current Debt data on file, last reported at $250000.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - | -8.44 Bn |
| 2 | Teva Pharmaceutical Industries | 43.28 Bn | 39.62 Bn | 2.15 Bn | 12.09 Bn |
| 3 | Zoetis | 31.79 Bn | 30.11 Bn | 1.05 Bn | 9.05 Bn |
| 4 | Takeda Pharmaceutical | 28.69 Bn | 22.89 Bn | 5.10 Bn | 27.73 Bn |
| 5 | United Therapeutics | 22.25 Bn | 19.58 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 11.61 Bn |
| 7 | Neurocrine Biosciences | 15.58 Bn | 15.19 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 11.87 Bn | 11.34 Bn | 798.00 Mn | 3.85 Bn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | 130.00 Mn |
| 10 | Apimeds Pharmaceuticals US | 7.50 Mn | 7.50 Mn | - | 5.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 250,000.00 |